抗桥尾蛋白抗体:系统性硬化症患者中一种与下肠道功能障碍相关的新特异性抗体
研究从一例伴胃肠道功能障碍但无已知系统性硬化症相关自身抗体的患者血清中发现桥尾蛋白为新自身抗原。抗桥尾蛋白抗体见于9%的系统性硬化症患者(16/188),健康对照0/46,且与便秘评分升高及严重便秘、严重腹胀相关。
要点
- 抗桥尾蛋白抗体见于9%的系统性硬化症患者(16/188),健康对照0/46。
- 抗体阳性者便秘评分1.00 vs 0.50(P=0.02),严重便秘46% vs 15%(P=0.005)、严重腹胀54% vs 25%(P=0.023)更常见。
- 桥尾蛋白表达于肠神经系统,抗桥尾蛋白抗体与系统性硬化症患者便秘的存在及严重程度相关。
核心结论
- 桥尾蛋白是一种表达于人肌间神经丛神经节的新型肠神经系统自身抗原。
- 抗桥尾蛋白自身抗体与系统性硬化症患者便秘的存在及严重程度相关。
研究设计与样本
- 用一例伴胃肠道功能障碍但无已知系统性硬化症相关自身抗体的系统性硬化症患者血清进行自身抗体发现。
- 以小鼠肌间神经丛裂解物行免疫沉淀,-on-bead消化后经质谱鉴定自身抗原。
- 在系统性硬化症队列中确定患病率并用回归分析评估与新型自身抗体相关的临床特征。
- 用免疫组化检查桥尾蛋白在人胃肠道组织中的表达。
主要发现
- 抗桥尾蛋白抗体见于9%的系统性硬化症患者(16/188),健康对照0/46。
- 抗桥尾蛋白抗体阳性患者便秘评分1.00 vs 0.50(P=0.02)。
- 抗桥尾蛋白抗体阳性患者严重便秘46% vs 15%(P=0.005),严重腹胀54% vs 25%(P=0.023)。
- 严重便秘患者抗桥尾蛋白抗体水平0.04 vs 0.00(P=0.001),严重腹胀患者0.03 vs 0.004(P=0.010)。
- 在校正模型中,严重便秘仍与抗桥尾蛋白抗体相关。
关键数值与推荐
- 抗桥尾蛋白抗体在系统性硬化症患者中患病率为9%(16/188),健康对照为0/46。
- 严重便秘患者抗桥尾蛋白抗体水平0.04 vs 0.00(P=0.001)。
- 严重腹胀患者抗桥尾蛋白抗体水平0.03 vs 0.004(P=0.010)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Autoantibodies are clinically useful in phenotyping patients with systemic sclerosis (SSc). Gastrointestinal (GI) function is regulated by the enteric nervous system (ENS) and commonly impaired in SSc, suggesting that the SSc autoimmune response may target ENS antigens. We sought to identify novel anti-ENS autoantibodies with an aim to clinically phenotype SSc GI dysfunction. METHODS: Serum from a patient with SSc with GI dysfunction but without defined SSc-associated autoantibodies was used for autoantibody discovery. Immunoprecipitations performed with murine myenteric plexus lysates were on-bead digested, and autoantigens were identified by mass spectrometry. Prevalence was determined, and clinical features associated with novel autoantibodies were evaluated in a SSc cohort using regression analyses. The expression of gephyrin in human GI tract tissue was examined by immunohistochemistry. RESULTS: We identified gephyrin as a novel SSc autoantigen. Anti-gephyrin antibodies were present in 9% of patients with SSc (16/188) and absent in healthy controls (0/46). Anti-gephyrin antibody-positive patients had higher constipation scores (1.00 vs 0.50, P = 0.02) and were more likely to have severe constipation and severe distention/bloating (46% vs 15%, P = 0.005; 54% vs 25%, P = 0.023, respectively). Anti-gephyrin antibody levels were significantly higher among patients with severe constipation (0.04 vs 0.00; P = 0.001) and severe distention and bloating (0.03 vs 0.004; P = 0.010). Severe constipation was associated with anti-gephyrin antibodies even in the adjusted model. Importantly, gephyrin was expressed in the ENS, which regulates gut motility. CONCLUSION: Gephyrin is a novel ENS autoantigen that is expressed in human myenteric ganglia. Anti-gephyrin autoantibodies are associated with the presence and severity of constipation in patients with SSc.
引用
- McMahan ZH, Kulkarni S, Andrade F, et al. Anti-Gephyrin Antibodies: A Novel Specificity in Patients With Systemic Sclerosis and Lower Bowel Dysfunction. Arthritis Rheumatol. 2023. PMID: 37530745. doi:10.1002/art.42667
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。